Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Athenex Inc (ATNX)

Athenex Inc (ATNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire - Mon May 1, 2023

/PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation...

ATNX : 0.2031 (-23.39%)
First Republic, Athenex fall; Franchise Group, Exelixis rise Associated Press - Mon Mar 20, 2023

Stocks that traded heavily or had substantial price changes Monday: First Republic, Athenex fall; Franchise Group, Exelixis rise

NYCB : 10.55 (-8.26%)
SBNY : 1.2400 (+3.33%)
FL : 23.13 (+3.03%)
EXEL : 35.61 (+2.24%)
FRC : 3.51 (-43.30%)
SPGI : 514.46 (+0.60%)
ATNX : 0.2031 (-23.39%)
Athenex: Q4 Earnings Snapshot AP - Mon Mar 20, 2023

Athenex: Q4 Earnings Snapshot

ATNX : 0.2031 (-23.39%)
Athenex: Q3 Earnings Snapshot AP - Thu Nov 3, 2022

Athenex: Q3 Earnings Snapshot

ATNX : 0.2031 (-23.39%)
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants Globe Newswire - Thu Aug 11, 2022

BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.2031 (-23.39%)
Athenex Provides Second Quarter 2022 Financial Results and Business Update Globe Newswire - Thu Jul 28, 2022

Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds...

ATNX : 0.2031 (-23.39%)
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology Globe Newswire - Mon Jul 25, 2022

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.2031 (-23.39%)
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022 Globe Newswire - Thu Jul 21, 2022

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and...

ATNX : 0.2031 (-23.39%)
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd. Globe Newswire - Mon Jul 11, 2022

Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will be used...

ATNX : 0.2031 (-23.39%)
Athenex to Participate in Truist Securities Cell Therapy Symposium Globe Newswire - Thu Jun 23, 2022

BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and...

ATNX : 0.2031 (-23.39%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - Fri Nov 22, 6:00PM CST
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot